Sweeping structural changes and scientific breakthroughs are
driving demand for new products, services and technologies
Athersys, Inc. (NASDAQ:ATHX) is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders.
Ambit Biosciences Corp. was acquired by Daiichi Sankyo (TYO: 4568) in November of 2014. The company is focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers of those diseases. Ambit’s lead drug candidate, Quizartinib, is a once-daily, orally-administered kinase inhibitor currently in Phase 2b clinical development in patients with relapsed/refractory acute myeloid leukemia, or AML. Ambit completed an IPO in May 2013.
Amicus Therapeutics, Inc.
(NASDAQ:FOLD) is a biotechnology company developing small-molecule,
orally-active drugs, known as Pharmacological Chaperones for treating human
genetic disorders. Pharmacological chaperones are designed to help mutant
proteins fold correctly into their normal 3-dimensional conformations,
rescuing intrinsic biological activity and function. Amicus completed an IPO
in May 2007.
Corus Pharma, Inc. was acquired by Gilead Sciences in August 2006. Prior to the acquisition, Corus was developing small molecule drugs for the treatment of respiratory diseases.